{"id":295330,"date":"2025-02-20T00:00:00","date_gmt":"2025-02-20T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0010-2022-biopharma-malignant-melanoma-current-treatment-current-treatment-physician-insights\/"},"modified":"2026-04-17T11:18:24","modified_gmt":"2026-04-17T11:18:24","slug":"cutron0010-2025-biopharma-malignant-melanoma-current-treatment-current-treatment-physician-insights-malignant-melanoma","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0010-2025-biopharma-malignant-melanoma-current-treatment-current-treatment-physician-insights-malignant-melanoma\/","title":{"rendered":"Malignant Melanoma &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Malignant Melanoma (US)"},"content":{"rendered":"<p>Disease stage, primary tumor resectability, and <i><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr> <\/i>mutation status are some of the key parameters influencing the treatment of malignant melanoma. For patients with <i><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr> <\/i>mutations, <abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr>\/<abbr title=\"mitogen-activated protein kinase kinase\">MEK<\/abbr> inhibitor combination regimens such as Roche\/Genentech\u2019s Zelboraf + Cotellic \u00b1 Tecentriq, Novartis\u2019s Tafinlar + Mekinist, and Pfizer\u2019s Braftovi + Mektovi are key options. Immune checkpoint inhibitors, including Keytruda (Merck &#038; Co.), Opdivo \u00b1 Yervoy (Bristol Myers Squibb), and Opdualag (Bristol Myers Squibb), along with Iovance Biotherapeutics\u2019 Amtagvi, an autologous <abbr title=\"tumor-infiltrating lymphocyte\">TIL<\/abbr> therapy, can be used regardless of mutation status. Intratumoral treatments are limited to Amgen\u2019s oncolytic viral therapy Imlygic, which is available only for patients with injectable lesions that cannot be surgically removed. This content evaluates the critical determinants influencing medical oncologists\u2019 prescribing choices in the treatment of malignant melanoma.<\/p>\n<p>QUESTIONS ANSWERED<\/p>\n<ul class=\"round-bullets\">\n<li>What are the current treatment practices in the adjuvant setting, and what factors influence the use of <abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr>\/<abbr title=\"mitogen-activated protein kinase kinase\">MEK<\/abbr> inhibitors versus anti-<abbr title=\"programmed cell death-1\">PD-1<\/abbr> therapy?<\/li>\n<li>What is the uptake of immune checkpoint inhibitors and <abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr>\/<abbr title=\"mitogen-activated protein kinase kinase\">MEK<\/abbr> inhibitors in the treatment of <i><abbr title=\"virus-induced rapidly accelerating fibrosarcoma murine sarcoma viral oncogene homolog B1\">BRAF<\/abbr><\/i>-mutation-positive malignant melanoma?<\/li>\n<li>How do drug-treatment rates vary across key patient populations according to stage of disease and line of therapy?<\/li>\n<li>Which drivers and constraints influence treatment decisions regarding key targeted therapies in the unresectable or metastatic setting?<\/li>\n<\/ul>\n<p><strong>Market covered:<\/strong> United States.<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 100 U.S. medical oncologists in December 2024.<\/p>\n<p><strong>Key drugs covered: <\/strong>Keytruda, Opdualag, Amtagvi, Opdivo \u00b1 Yervoy, Zelboraf, Cotellic, Tafinlar, Mekinist, Braftovi, Mektovi, Imlygic.<\/p>\n<p><strong>PRODUCT <\/strong><strong>DESCRIPTION<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-295330","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-therapy-areas-solid-tumors","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295330\/revisions"}],"predecessor-version":[{"id":575821,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295330\/revisions\/575821"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}